Undisclosed oral IL-17 inhibitor / Pepticom - LARVOL DELTA

Pepticom Announces Successful Completion of Series A1 Funding Round (PRNewswire) - "Pepticom, a pioneer in AI-driven peptide-based therapeutics, today announced the successful completion of its Series A1 funding round, securing $6.6 million. Japan Israel High Tech Ventures 2 LP led the round, with strong participation from existing investors....This funding will accelerate the development of Pepticom's oral IL-17 inhibitor program, targeting improved treatments for autoimmune diseases. This includes the design of two families of fully synthetic, small cyclic peptidomimetic inhibitors with nanomolar activity that target both IL-17A and IL-17F isoforms."

Financing • Immunology